Ardent Health Partners, Inc.
ARDT
$14.97
-$0.35-2.29%
| Weiss Ratings | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.60% | |||
| 30-Day Total Return | 2.96% | |||
| 60-Day Total Return | -6.44% | |||
| 90-Day Total Return | -22.44% | |||
| Year to Date Total Return | -11.16% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -26.06% | |||
| 52-Week Low % Change | 13.06% | |||
| Price | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $20.72 | |||
| 52-Week Low Price | $13.55 | |||
| 52-Week Low Price (Date) | Feb 28, 2025 | |||
| 52-Week High Price (Date) | Oct 16, 2024 | |||
| Valuation | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.19B | |||
| Enterprise Value | 4.29B | |||
| Price/Earnings (TTM) | 11.01 | |||
| Earnings Per Share (TTM) | 1.39 | |||
| Earnings Per Share Growth | 252.48% | |||
| Price/Earnings To Growth | 0.04 | |||
| Price/Sales (TTM) | 0.36 | |||
| Price/Book (Q) | 1.93 | |||
| Enterprise Value/Revenue (TTM) | 0.72 | |||
| Price | $14.97 | |||
| Enterprise Value/EBITDA (TTM) | 7.78 | |||
| Enterprise Value/EBIT | 10.58 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 140.83M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 615 296 3000 | |||
| Address | 340 Seven Springs Way Brentwood, TN 37027 | |||
| Website | www.ardenthealth.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 6.80% | |||
| Profit Margin | 3.52% | |||
| Management Effectiveness | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.24% | |||
| Return on Equity | 23.01% | |||
| Income Statement | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.94B | |||
| Total Revenue (TTM) | 5.97B | |||
| Revenue Per Share | $42.36 | |||
| Gross Profit (TTM) | 3.43B | |||
| EBITDA (TTM) | 552.05M | |||
| EBIT (TTM) | 405.76M | |||
| Net Income (TTM) | 210.34M | |||
| Net Income Avl. to Common (TTM) | 210.34M | |||
| Total Revenue Growth (Q YOY) | 19.33% | |||
| Earnings Growth (Q YOY) | 1,206.85% | |||
| EPS Diluted (TTM) | 1.39 | |||
| EPS Diluted Growth (Q YOY) | 2,550.15% | |||
| Balance Sheet | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 566.70M | |||
| Cash Per Share (Q) | $4.02 | |||
| Total Current Assets (Q) | 1.83B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.52B | |||
| Current Ratio (Q) | 1.939 | |||
| Book Value Per Share (Q) | $7.93 | |||
| Total Assets (Q) | 4.96B | |||
| Total Current Liabilities (Q) | 945.42M | |||
| Total Debt (Q) | 2.28B | |||
| Total Liabilities (Q) | 3.43B | |||
| Total Common Equity (Q) | 1.13B | |||
| Cash Flow | ARDT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -220.46M | |||
| Cash from Financing (TTM) | 24.64M | |||
| Net Change in Cash (TTM) | 119.21M | |||
| Levered Free Cash Flow (TTM) | 53.34M | |||
| Cash from Operations (TTM) | 315.03M | |||
